MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites
- PMID: 32573818
- DOI: 10.1111/apt.15882
MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites
Abstract
Background: The Model for Endstage Liver Disease (MELD) score may put patients with severe ascites at a disadvantage because they often have a poor quality of life and high mortality despite a favourable MELD score.
Aim: To develop a model that is better than the MELD score at predicting 1-year mortality among patients with cirrhosis, severe ascites and MELD ≤18.
Methods: We used data from a randomised trial (SPARe-1) of patients with cirrhosis and severe ascites to develop a model to predict 1-year mortality. We used stepwise backward elimination and Cox regression to identify the strongest predictors. Performance was assessed with the C index and the Brier score. We examined performance in an external cohort of trial participants with cirrhosis and severe ascites (SPARe-2 participants).
Results: We included 308 patients with a 1-year mortality of 20.4%. The final prediction model (Severe Ascites Mortality score, "SAM score") included four variables: serum bilirubin, serum sodium, history of SBP (yes or no) and diabetes (yes or no). No indicators of quality of life were included. After correction for optimism bias, the SAM and MELD scores had nearly identical predictive ability. The external validation cohort included 149 patients whose 1-year mortality was 22.4%. The MELD score performed marginally better in this cohort, partly because the effects of SBP and diabetes on mortality were much smaller in this cohort.
Conclusion: We did not succeed in developing a prediction model that was superior to the MELD score among patients with cirrhosis and severe ascites.
© 2020 John Wiley & Sons Ltd.
Comment in
-
Editorial: current challenges in predicting mortality in patients with cirrhosis and refractory ascites.Aliment Pharmacol Ther. 2020 Sep;52(5):885-886. doi: 10.1111/apt.15982. Aliment Pharmacol Ther. 2020. PMID: 32852822 No abstract available.
Similar articles
-
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.Hepatology. 2004 Oct;40(4):802-10. doi: 10.1002/hep.20405. Hepatology. 2004. PMID: 15382176
-
Prognostic Significance of Ascites and Serum Sodium in Patients with Low Meld Scores.Med Arch. 2016 Feb;70(1):48-52. doi: 10.5455/medarh.2016.70.48-52. Epub 2016 Jan 31. Med Arch. 2016. PMID: 26980932 Free PMC article.
-
Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites.J Hepatol. 2012 Aug;57(2):274-80. doi: 10.1016/j.jhep.2012.03.018. Epub 2012 Apr 17. J Hepatol. 2012. PMID: 22521353
-
Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.J Gastroenterol Hepatol. 2009 Sep;24(9):1547-53. doi: 10.1111/j.1440-1746.2009.05913.x. Epub 2009 Aug 3. J Gastroenterol Hepatol. 2009. PMID: 19686416
-
EVALUATION OF PROGNOSTIC FACTORS IN DECOMPENSATED LIVER CIRRHOSIS WITH ASCITES AND SPONTANEOUS BACTERIAL PERITONITIS.Rev Med Chir Soc Med Nat Iasi. 2015 Oct-Dec;119(4):1018-24. Rev Med Chir Soc Med Nat Iasi. 2015. PMID: 26793843
Cited by
-
A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study.PLoS Negl Trop Dis. 2025 May 27;19(5):e0013134. doi: 10.1371/journal.pntd.0013134. eCollection 2025 May. PLoS Negl Trop Dis. 2025. PMID: 40424464 Free PMC article.
-
Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.Hepatol Int. 2022 Dec;16(6):1468-1483. doi: 10.1007/s12072-022-10374-z. Epub 2022 Sep 1. Hepatol Int. 2022. PMID: 36048318
-
Artificial intelligence-based evaluation of prognosis in cirrhosis.J Transl Med. 2024 Oct 14;22(1):933. doi: 10.1186/s12967-024-05726-2. J Transl Med. 2024. PMID: 39402630 Free PMC article. Review.
-
Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis.Tomography. 2024 Mar 25;10(4):471-479. doi: 10.3390/tomography10040036. Tomography. 2024. PMID: 38668394 Free PMC article.
-
Gut microbiome and metabolome signatures in liver cirrhosis-related complications.Clin Mol Hepatol. 2024 Oct;30(4):845-862. doi: 10.3350/cmh.2024.0349. Epub 2024 Jul 25. Clin Mol Hepatol. 2024. PMID: 39048520 Free PMC article.
References
REFERENCES
-
- Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802-810.
-
- Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl. 2011;17:129-136.
-
- Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease (MELD) exception for ascites. Liver Transpl. 2006;12:S88-90.
-
- Atiemo K, Skaro A, Maddur H, et al. Mortality risk factors among patients with cirrhosis and a low model for end-stage liver disease sodium score (≤15): An analysis of liver transplant allocation policy using aggregated electronic health record data. Am J Transplant. 2017;17:2410-2419.
-
- United Network for Organ Sharing. Clerical changes for implementation of adding serum sodium to the MELD score. https://optn.transplant.hrsa.gov/media/1575/policynotice_20151101.pdf. Accessed 8 April 2020.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical